Ziopharm says ZIO-201/202/203 shows anticancer activity in leukemia, pancreas, prostate cancers

By Elaine Rigoli

Tampa, Fla., April 3 - Ziopharm Oncology, Inc. data from preclinical studies of ZIO-201 and two halogenated analogs, ZIO-202 and ZIO-203, show anticancer activity.

These data show ZIO-201 is active against cisplatin-resistant leukemia cells. ZIO-201 and cisplatin had similar activity in leukemia cells (P388) sensitive to cisplatin but ZIO-201 had about an eight-log cell kill greater antileukemia activity against cisplatin-resistant cells, according to a news release.

The data also show that anticancer activities of ZIO-201, ZIO-202 and ZIO-203 are similar in human pancreas and prostate cancer xenografts and that many schedules were active.

ZIO-201, the company's proprietary alkylating drug and the active metabolite of ifosfamide, is currently in a phase 1/2 clinical trial in advanced sarcoma, the release said.

Ziopharm said it plans to start additional phase 2 studies in the near future with a pivotal registration trial in 2007.

The company said ZIO-202 and ZIO-203 will be further differentiated in preclinical studies.

Based in New York, Ziopharm is a biopharmaceutical company engaged in the development and commercialization of in-licensed cancer drugs to address unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.